Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy: A Randomized Controlled Trial (SUPER).

Autor: Skougaard K; Department of Nuclear Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark; Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark., Østrup O; Department of Genomic Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark., Guldbrandsen K; Department of Nuclear Medicine, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark., Sørensen B; Department of Clinical Biochemistry, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark., Meldgaard P; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark., Saghir Z; Department of Pulmonology, Copenhagen University Hospital Gentofte, Hellerup, Denmark., Gørtz P; Department of Nuclear Medicine, Copenhagen University Hospital Gentofte, Hellerup, Denmark., Lonsdale MN; Department of Nuclear Medicine, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark., Frank MS; Department of Oncology, Zealand University Hospital Næstved, Næstved, Denmark., Gerke O; Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark., Rychwicka-Kielek BA; Department of Pulmonology, Aalborg University Hospital, Aalborg, Denmark., Persson G; Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark., Land LH; Department of Oncology, Odense University Hospital, Odense, Denmark., Schytte T; Department of Oncology, Odense University Hospital, Odense, Denmark., Bodtger U; Department of Pulmonology, Zealand University Hospital Næstved, Næstved, Denmark., Skuladottir H; Department of Oncology, Regional Hospital Herning, Herning, Denmark., Søgaard J; Institute of Health Economics, University of Southern Denmark, Odense, Denmark., Nielsen SS; Department of Nuclear Medicine, Aalborg University Hospital, Aalborg, Denmark., Rasmussen TR; Department of Pulmonology, Aarhus University Hospital, Aarhus, Denmark., Fischer BM; Department of Nuclear Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark; PET Center, School of Biomedical Engineering and Imaging Sciences Kings College London, St Thomas' Hospital, London, UK. Electronic address: barbara.malene.fischer@regionh.dk.
Jazyk: angličtina
Zdroj: Clinical lung cancer [Clin Lung Cancer] 2020 Mar; Vol. 21 (2), pp. e61-e64. Date of Electronic Publication: 2019 Nov 21.
DOI: 10.1016/j.cllc.2019.11.002
Abstrakt: Despite increased focus on prevention as well as improved treatment possibilities, lung cancer remains among the most frequent and deadliest cancer diagnoses worldwide. Even lung cancer patients treated with curative intent have a high risk of relapse, leading to a dismal prognosis. More knowledge on the efficacy of surveillance with both current and new technologies as well as on the impact on patient treatment, quality of life, and survival are urgently needed. We therefore designed a randomized phase 3 trial. In one arm, every other computed tomography (CT) scan is replaced by positron emission tomography/CT, the other arm is the standard follow-up scheme with CT. The standard arm is identical to the current national Danish follow-up program. The primary endpoint is to compare the number of relapses treatable with curative intent in the 2 arms. We aim to include 750 patients over a 3-year period. Additionally, we will test the feasibility of noninvasive lung cancer diagnostics and surveillance in the form of circulating tumor DNA analysis. For this purpose, blood samples are collected before treatment and at each following control. The blood samples are stored in a biobank for later analysis and will not be used for guiding patient treatment decisions.
(Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: